Budget impact analysis of capivasertib as a second-line therapy for advanced breast cancer in the United States
{{output}}
Background: Capivasertib was the first AKT inhibitor approved by the US FDA as a second-line treatment for PIK3CA/AKT1/PTEN-altered, HR+/HER2- advanced breast cancer. However, capivasertib is costly. This study provides the first... ...
